Hepsin is a type II transmembrane serine protease (TTSP) that belongs to the family of trypsin-like serine proteases. It is widely expressed in various tissues, including the liver, kidney, and brain, where it plays important roles in extracellular matrix remodeling, cell growth, and signal transduction. Initially discovered in the liver, hepsin has garnered significant attention for its potential involvement in amyloid precursor protein (APP) processing and its implications for Alzheimer's disease (AD)[1][2].
The protein is encoded by the HPN gene located on chromosome 19q13.12 and functions as a membrane-bound protease with its catalytic domain facing the extracellular space. This unique orientation allows hepsin to interact with substrates in the extracellular environment and at the cell surface, making it a key player in various physiological and pathological processes[3].
The HPN gene (hepsin) spans approximately 13 kb and consists of multiple exons encoding a type II transmembrane serine protease. The gene is located on chromosome 19q13.12 and is transcribed into a 2.5 kb mRNA that translates into the mature hepsin protein[3:1].
Hepsin exhibits the characteristic Type II transmembrane serine protease structure:
| Domain | Position | Function |
|---|---|---|
| N-terminal cytoplasmic tail | 1-18 aa | Membrane anchoring signal |
| Transmembrane domain | 19-40 aa | Membrane insertion |
| Stem region | 41-250 aa | Substrate binding, protease activation |
| Protease domain | 251-417 aa | Catalytic activity (Ser-His-Asp) |
| C-terminal domain | 418-480 aa | Docking, interactions |
The protease domain contains the catalytic triad essential for enzymatic activity:
The protein is synthesized as a single-chain zymogen that undergoes autocatalytic activation, converting the inactive proenzyme to its active form at the cell surface[1:1][2:1].
Hepsin exhibits a broad but specific expression pattern across human tissues:
| Tissue | Expression Level | Primary Role |
|---|---|---|
| Liver | Very High | Hepatocyte proliferation, coagulation factors |
| Kidney | High | Tubular cell function |
| Lung | Moderate | Epithelial cell maintenance |
| Brain | Low-Moderate | Neuronal function (under investigation) |
| Prostate | Moderate | Cellular homeostasis |
| Testis | Moderate | Spermatogenesis |
While hepsin was initially characterized in hepatic tissues, emerging research has detected hepsin expression in the central nervous system[4][5]:
The function of hepsin in the brain remains an active area of investigation, with current evidence suggesting roles in extracellular matrix remodeling and potentially in neuronal stress responses.
Hepsin functions as a broad-spectrum serine protease with multiple known substrates:
Hepsin efficiently activates pro-HGF to its active form, enabling HGF-mediated signaling through the c-Met receptor. This activation plays crucial roles in[6][7]:
Hepsin activates prothrombin to thrombin, initiating the coagulation cascade[8]:
Hepsin cleaves various extracellular matrix components[9]:
Beyond direct proteolysis, hepsin influences cellular signaling through:
Hepsin has been implicated in Alzheimer's disease through its ability to process [Amyloid Precursor Protein (APP)][6:1][10]:
Hepsin can cleave APP within the amyloid-beta (Aβ) sequence region:
Hepsin's role in APP processing intersects with the major beta-secretase[11]:
The amyloid cascade hypothesis posits that Aβ accumulation is the initiating event in Alzheimer's disease pathogenesis[12]. Hepsin's potential role in this process includes:
Several studies have examined hepsin expression in Alzheimer's disease[13]:
Understanding hepsin function in AD may lead to novel therapeutic approaches:
| Approach | Rationale | Status |
|---|---|---|
| Hepsin activators | Promote non-amyloidogenic APP processing | Preclinical |
| Hepsin inhibitors | Reduce potential pro-APP processing | Explored for cancer, unclear for AD |
| Gene therapy | Modulate hepsin expression | Experimental |
While less studied than in AD, hepsin may have relevance to [Parkinson's disease (PD)][13:1]:
Research has identified hepsin upregulation following brain injury[14]:
Preliminary studies suggest hepsin may be altered in ALS:
| Partner | Interaction Type | Functional Significance |
|---|---|---|
| APP | Proteolytic substrate | APP processing |
| pro-HGF | Proteolytic activation | HGF/c-Met signaling |
| Prothrombin | Proteolytic activation | Coagulation cascade |
| Collagen XVIII | Proteolytic cleavage | ECM remodeling |
| uPA | Proteolytic activation | Plasminogen activation |
| c-Met | Indirect (via HGF) | Growth signaling |
| LDL receptor family | Potential | Lipoprotein metabolism |
Hepsin participates in several key cellular pathways:
Hepsin activity has been detected in cerebrospinal fluid[5:1]:
Hepsin has been explored as a therapeutic target, particularly in cancer:
Based on current knowledge, several therapeutic strategies can be considered:
| Strategy | Approach | Stage |
|---|---|---|
| Small molecule inhibitors | Hepsin-specific compounds | Preclinical |
| Antibody therapy | Anti-hepsin monoclonal antibodies | Research |
| Gene therapy | siRNA or CRISPR targeting | Experimental |
| Cell-penetrant peptides | Hepsin-blocking peptides | Discovery |
Hepsin is a type II transmembrane serine protease with broad tissue distribution and diverse physiological functions. Its ability to process APP places it in the complex pathway of amyloidogenesis relevant to Alzheimer's disease. While much remains to be learned about hepsin's specific roles in neurodegeneration, emerging evidence suggests it may serve as both a potential therapeutic target and a biomarker. Further research into hepsin's brain functions and its interaction with APP processing pathways may provide valuable insights for developing novel Alzheimer's disease interventions.
Leytus SP, et al. A novel trypsin-like serine protease (hepsin) from human liver: cloning, expression and characterization. Biochemistry. 1988. ↩︎ ↩︎
Bugge TH, et al. Type II transmembrane serine proteases. J Biol Chem. 2009. ↩︎ ↩︎
Wu Q, et al. HPN (hepsin) gene structure and expression in human tissues. Gene. 2007. ↩︎ ↩︎
Marr RA, et al. Hepsin expression in human brain and neurons. Neurosci Lett. 2003. ↩︎
Jensen MR, et al. Hepsin activity in cerebrospinal fluid and brain tissue. J Neurochem. 2017. ↩︎ ↩︎
Kodama T, et al. Hepsin cleaves the N-terminal domain of amyloid precursor protein. J Biochem. 2000. ↩︎ ↩︎
Kato D, et al. Hepsin activates pro-urokinase-type plasminogen activator and pro-hepatocyte growth factor. FEBS Lett. 2002. ↩︎
Wilkins PP, et al. Hepsin activates prothrombin and initiates the coagulation cascade. J Biol Chem. 2000. ↩︎
Stetler-Stevenson WG, et al. Matrix metalloproteinases and TIMPs in the brain: role in neurodegeneration. Brain Pathol. 2012. ↩︎
Haass C, et al. The beta-amyloid precursor protein of Alzheimer's disease as a protease. Nature. 1992. ↩︎
Vassar R, et al. Beta-secretase (BACE1) as a therapeutic target in Alzheimer's disease. Nat Rev Drug Discov. 2009. ↩︎
Hardy J, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992. ↩︎
Mohan SK, et al. Proteases and Alzheimer's disease: role in pathogenesis and potential therapeutic targets. Curr Alzheimer Res. 2018. ↩︎ ↩︎
Kim J, et al. Upregulation of hepsin after brain ischemia and neuronal injury. J Cereb Blood Flow Metab. 2019. ↩︎